Form 4: Chimerix Director Victoria Vakiener Granted Stock Options

Victoria Vakiener, a director at Chimerix, Inc., was granted stock options to purchase 60,000 shares of common stock on June 20, 2024.

Summary

• On June 20, 2024, Victoria Vakiener, a director of Chimerix, Inc. (CMRX), was granted stock options.
• These options allow her to purchase 60,000 shares of Chimerix common stock at an exercise price of $0.89 per share.
• The options vest in 12 equal monthly installments from the grant date, but will be fully vested by the earlier of the one-year anniversary of the grant date or the date of the company's 2024 annual stockholder meeting.
• Following this transaction, Vakiener directly owns 60,000 derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock option grants, and does not inherently convey positive or negative sentiment. It's a neutral disclosure.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders, potentially incentivizing them to work towards increasing the company's value.

Future Outlook

The document does not contain specific forward-looking statements about Chimerix's future performance.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders. This filing is a routine disclosure of such a grant.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.
• It also incentivizes the director, potentially leading to decisions that benefit the company and its stakeholders.

Key Dates